Subject Expert Committee of CDSCO recommended amendment of indication of Typhoid Vi conjugate vaccine of Zydus Lifesciences to include the age group of 45-65 years for single dose only.
Earlier, Zydus Lifesciences had presented its proposal for grant of permission for the additional indication of Typhoid Vi conjugate vaccine for age group 45-65 years along with the Phase III clinical trial report.
- Read more about Typhoid vaccine of Zydus marks additional indication from CDSCO panel
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/typhoid-vaccine-zydus-marks-additional-indication-cdsco-panel
No comments:
Post a Comment